Dyne Therapeutics (NASDAQ:DYN) Trading Down 4.2% – What’s Next?

Dyne Therapeutics, Inc. (NASDAQ:DYN)’s share price dropped 4.2% during mid-day trading on Friday . The company traded as low as $29.73 and last traded at $29.82. Approximately 176,628 shares were traded during mid-day trading, a decline of 88% from the average daily volume of 1,474,617 shares. The stock had previously closed at $31.13.

Analysts Set New Price Targets

DYN has been the topic of several research reports. StockNews.com downgraded shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 16th. Chardan Capital reissued a “buy” rating and set a $50.00 price target on shares of Dyne Therapeutics in a research note on Wednesday, November 13th. Oppenheimer reissued an “outperform” rating and issued a $55.00 price target on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. JPMorgan Chase & Co. cut Dyne Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $43.00 to $35.00 in a report on Thursday, October 24th. Finally, Royal Bank of Canada started coverage on shares of Dyne Therapeutics in a research report on Tuesday, November 26th. They set an “outperform” rating and a $45.00 price target for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Dyne Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $50.82.

Dyne Therapeutics Trading Down 1.7 %

The company has a market cap of $3.12 billion, a price-to-earnings ratio of -8.60 and a beta of 1.10. The firm’s fifty day moving average price is $31.66 and its 200-day moving average price is $35.39.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). As a group, research analysts anticipate that Dyne Therapeutics, Inc. will post -3.45 EPS for the current year.

Insider Activity

In other news, Director Carlo Incerti sold 16,500 shares of the business’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $28.73, for a total value of $474,045.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Jason P. Rhodes sold 782 shares of the stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $33.10, for a total value of $25,884.20. Following the transaction, the director now owns 15,962 shares of the company’s stock, valued at approximately $528,342.20. The trade was a 4.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 176,257 shares of company stock worth $6,193,718 over the last quarter. 20.77% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC lifted its position in Dyne Therapeutics by 904.1% during the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock worth $26,000 after buying an additional 669 shares in the last quarter. Quantbot Technologies LP bought a new stake in Dyne Therapeutics during the third quarter worth about $34,000. Point72 DIFC Ltd acquired a new position in Dyne Therapeutics during the third quarter valued at approximately $36,000. US Bancorp DE grew its stake in Dyne Therapeutics by 776.9% in the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after purchasing an additional 1,212 shares in the last quarter. Finally, Values First Advisors Inc. acquired a new position in shares of Dyne Therapeutics during the 3rd quarter worth approximately $62,000. Institutional investors and hedge funds own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.